Sparrow BioAcoustics has received a $10 million investment to help speed up the expansion of its Stethophone platform in hospitals across North America. The Stethophone is an FDA-approved cardiac AI system designed to detect structural and rhythmic heart issues using a smartphone, which makes high-quality cardiovascular screening more accessible. This funding will help the company grow while keeping a strong focus on clinical outcomes and patient care.
Health Technology Insights: RestorixHealth Acquires CūtisCare for Wound Center Services
Mark Opauszky, CEO of Sparrow BioAcoustics, explained that the funding will allow the company to carefully scale its operations and keep supporting hospitals and patients with dependable, high-quality cardiac AI tools. He stressed that the aim is to maintain the progress they have made so far and keep delivering meaningful clinical value.
Health Technology Insights: Verato Launches Identity Intelligence Agent with Salesforce Health
A study published in the International Journal of Medical Science and Innovation Research looked at the clinical performance of Sparrow’s Stethophone AI at the University of Washington Medical Center. Researchers found the system to be very accurate in identifying valvular disease and atrial fibrillation. The study pointed out the potential of the AI platform to change cardiac screening by using common smartphone technology to make quality cardiovascular assessments more widely available. It also noted that early detection of murmurs can lead to timely treatments and better patient outcomes.
The Stethophone is currently being tested at several clinical sites in the United States and Canada. Dr. Yaroslav Shpak, Chief Medical Officer and co-founder of Sparrow BioAcoustics, mentioned that in the past year, around 40,000 patients and healthcare providers have used the platform, uncovering many cardiac issues that might have gone unnoticed until later stages. He added that the need for scalable screening for conditions like aortic stenosis is growing and that feedback from both patients and clinicians has been very positive.
Sparrow BioAcoustics recently shared more updates at the Transcatheter Cardiovascular Therapeutics Conference in San Francisco and plans to showcase the Stethophone at the upcoming American Heart Association Scientific Sessions in New Orleans in early November. These events will highlight the system’s potential to improve access to cardiac care and show its ongoing clinical impact.
Health Technology Insights: Altius Teams with Syd Life AI to Launch Preventive Health LLM
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
